In light of the promising data by Rosenberg and colleagues [26] and hints of activity of vaccines directed against other antigens in a series of studies in Japan [31–36], the data presented here suggest that triggering an effective anti-SS response is not accomplished by CTLA-4 inhibition alone. Here, CTLA4 is linked to synovial sarcoma.